Skip to Content

Decode Ditches Drug Development

The revamped version of the company will focus on genetic research and diagnostics.
January 22, 2010

The Icelandic genomics company DeCode announced details of its rebirth yesterday, most notably dropping its drug development efforts. The company, which has churned out a huge body of genetic research in the last decade–much of it published in high profile scientific journals–filed for chapter 11 bankruptcy protection in the U.S late last year. The company has spent more than $600 million but never turned a profit.

Decode began as a sort of national genomics effort, capitalizing on Iceland’s self-contained population, well-documented genealogies, and openness to genetic research to search for genes linked to different diseases. (In the early days, these characteristics allowed scientists to pinpoint these genes more easily than in a general population.) As genomics technology advanced, the company moved to whole genome association studies, identifying genes linked to heart disease, stroke, skin cancer and schizophrenia. In the process, DeCode generated a massive genomics database, as well as expertise in collecting and analyzing huge volumes of data, which it now hopes to capitalize on. Rather than trying to develop drugs on its own, the company plans to partner with pharmaceutical firms.

The company will continue to offer its consumer genetic-testing website, deCodeME, launched in 2007.

According to the New York Times,

The new DeCode is owned by Saga Investments, an alliance that includes two leading life science investment companies, Polaris Ventures and ARCH Venture Partners. Terrance McGuire, a general partner at Polaris, said DeCode had been recapitalized because its research and database, formed from the medical records of the Icelandic population, were a valuable asset. “From an investor’s perspective, it was the power of the content being created,” he said.

…Dr. Stefansson said that the company’s genetic research in Iceland would carry on just as before and that DeCode would “continue to outperform” its mostly university-based rivals in the United States and England. The commercial operation will be lead by Mr. Collier in the United States, Dr. Stefansson said.

For more of TR’s coverage of DeCode, check out this Q&A with Kari Stefansson from 2006, which highlights the company’s high hopes for drug development. And this feature describing its early efforts.

Keep Reading

Most Popular

computation concept
computation concept

How AI is reinventing what computers are

Three key ways artificial intelligence is changing what it means to compute.

still from Embodied Intelligence video
still from Embodied Intelligence video

These weird virtual creatures evolve their bodies to solve problems

They show how intelligence and body plans are closely linked—and could unlock AI for robots.

seeing is believing concept
seeing is believing concept

Our brains exist in a state of “controlled hallucination”

Three new books lay bare the weirdness of how our brains process the world around us.

We reviewed three at-home covid tests. The results were mixed.

Over-the-counter coronavirus tests are finally available in the US. Some are more accurate and easier to use than others.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.